Table 1.

Patients with chronic rhinosinusitis with positive responses to PT

Patient	Phage preparation used in PT	Route of phage administration	Phage inactivation (K) before PT	Phage inactivation (K) during PTa	Day of PT on which K was marked	Clinical outcome of PT (A–C)b
1	Staph OPMS-1	Locally	0.74	28.28	62	C
2	Staph A5/80 Since 14th day of PT Staph 676/T	Locally	0.06 0.85	0.16 12.06	14 55	A
3	Pseud Psmw31	Locally and orally	0.00	0.002	14	B
4	Staph OPMS-1top	Locally and orally	0.25	4.25	15	C
5	Staph 676/T	Locally and orally	0.36	48.21	49	A
6	Staph 676/Z	Locally and orally	0.03	1.21	48	B
7	Klebs Kl 16/30 Coli 126/2031	Locally and orally	0.005 0.01	0.02 0.11	31	C
8	Staph A5/L	Locally and orally	0.03	0.72	14	C
			Mean K ± SD 0.23 ± 0.32	Mean K ± SD* 9.50 ± 16.28 (Wilcoxon test, p = 0.005)	14–62

K rate of phage inactivation, PT phage therapy, SD standard deviation

K < 5, low neutralization of phages

K = 5–18, medium neutralization of phages

K > 18, high neutralization of phages

^aMaximum K achieved during PT

^bResults A–C positive responses to PT

*Significantly associated with the increase in the K rate during PT compared to the K rate before PT (Wilcoxon test; p = 0.005). There was no statistically significant difference (Mann-Whitney U test; p = 0.65) in the K rate during PT between positive responses to PT (Table 1) and inadequate responses to PT (Table 2)